Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
Christine Ribic(Lunenfeld-Tanenbaum Research Institute), Steven Gallinger(Ontario Institute for Cancer Research), Daniel J. Sargent(National Institute of Agricultural Botany), Dongsheng Tu(Ontario Institute for Cancer Research), Stanley R. Hamilton(City of Hope), Richard M. Goldberg(Ontario Institute for Cancer Research), Amy J. French, Mark Redston(Brigham and Women's Hospital), Pierre Laurent‐Puig(Inserm), Stephen N. Thibodeau(Mayo Clinic in Arizona), Malcolm J. Moore(University Health Network), Robert Gryfe(Mount Sinai Hospital), Lois E. Shepherd(Ontario Institute for Cancer Research)
Cited by 2,150
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k